CHMP fandt også, at der var behov for særlige forsigtighedsregler for patienter med leverinsufficiens og/ eller cholestasis, da størstedelen af valsartan hovedsageligt elimineres som uforandret lægemiddel i galden via leverclearance.
The CHMP also considered that special precaution would be needed for patients with hepatic impairment and/ or cholestasis, as the majority of valsartan is eliminated, mainly as unchanged drug in the bile, by hepatic clearance.